Crescent Biopharma director granted 11,050 stock options
CRESCENT BIOPHARMA, INC. director Jonathan Violin received a grant of stock options covering 11,050 ordinary shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
CRESCENT BIOPHARMA, INC. director Jonathan Violin received a grant of stock options covering 11,050 ordinary shares. The options carry an exercise price of $17.01 per share and expire on June 2, 2036. They vest in full on the earlier of June 2, 2027 or the company’s next annual shareholder meeting, subject to his continued service.
Insider Trade Summary
Grant/Award: 11,050 shares
Grant/Award
1 txn
Insider
Violin Jonathan
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 11,050 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 11,050 contracts (Direct)
Footnotes (1)
- F1. This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer.
Key Figures
Option grant size: 11,050 options
Exercise price: $17.01 per share
Expiration date: June 2, 2036
+1 more
4 metrics
Option grant size
11,050 options
Stock Option (Right to Buy) grant to director
Exercise price
$17.01 per share
Exercise price of stock options
Expiration date
June 2, 2036
Option expiration for this grant
Post-grant derivative holdings
11,050 options
Total options following transaction
Key Terms
Stock Option (Right to Buy), exercise price, vests in full, annual meeting of shareholders
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "17.0100""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vests in full financial
"and vests in full on the earlier of (i) June 2, 2027"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CBIO director Jonathan Violin report?
Jonathan Violin reported receiving a grant of stock options for 11,050 ordinary shares of Crescent Biopharma. These options are a compensation-related award, not an open-market stock purchase or sale, and give him the right to buy shares at a fixed exercise price.
How many Crescent Biopharma (CBIO) options were granted to Jonathan Violin?
He was granted stock options over 11,050 ordinary shares of Crescent Biopharma. Following this grant, his reported derivative holdings from this award total 11,050 options, providing potential future equity exposure if the options vest and are later exercised.
What is the exercise price of Jonathan Violin’s CBIO stock options?
The options have an exercise price of $17.01 per share. This means Violin can buy Crescent Biopharma ordinary shares at $17.01 if he exercises the options after they vest and before they expire, regardless of the future market price at that time.
When do Jonathan Violin’s Crescent Biopharma stock options vest?
The options vest in full on the earlier of June 2, 2027 or the date of Crescent Biopharma’s next annual meeting of shareholders. Vesting is contingent on Violin’s continued service to the company through the applicable vesting date, according to the filing footnote.
When do Jonathan Violin’s CBIO stock options expire if unexercised?
The stock options are scheduled to expire on June 2, 2036. After that expiration date, any unexercised options will lapse and can no longer be used to acquire Crescent Biopharma ordinary shares, even if they had previously vested under the award terms.
Is Jonathan Violin’s CBIO Form 4 transaction a stock purchase or sale?
The reported transaction is a grant of stock options, not a direct purchase or sale of shares. It reflects a compensation award giving Violin the right to buy shares at $17.01 in the future, subject to vesting and his continued service with Crescent Biopharma.
AI-generated analysis. How Rhea-AI works. Not financial advice.
